CLS provides minimally invasive, cost-efficient solutions for soft tissue resection in patients with complex medical conditions. Using high-precision laser energy, guided by imaging and real-time control, our patented thermotherapy platform enables safe, effective thermal ablation.

Focused initially on neurosurgery, CLS is expanding into adjacent areas. CLS’s business focuses on in-house development and market approval of medical devices. Our regulatory-approved devices are then commercialized through strategic partners in the U.S. and Europe, with a vision to do so on a global scale.

 Our business model generates >60% gross margin with revenue from system sales and recurring revenue from procedure-based disposables, and supports rapid scaling across multiple therapeutic areas with minimal fixed costs.